Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Affiliations

• ¹ Virginia G. Piper Cancer Center/TGen, Scottsdale, AZ, 85004, USA.
• ² Virginia G. Piper Cancer Center/TGen, Scottsdale, AZ, 85004, USA. [email protected].
• ³ Erasmus MC Cancer Institute, PO Box 2040, 3015 GD, Rotterdam, The Netherlands.
• ⁴ The University of Texas MD Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX, USA.
• ⁵ US Oncology Research, Texas Oncology, 910 E. Houston St., Suite 100, Tyler, TX, 75702, USA.
• ⁶ Pharmaceutical Division, Bayer AG, Müllerstraße 178, 13353, Berlin, Germany.
• ⁷ Bayer HealthCare Pharmaceuticals, Inc, 100 Bayer Blvd, Whippany, NJ, 07981, USA.
• ⁸ Chrestos Concept GmbH & Co. KG, Girardetstr. 1-5, 45131, Essen, Germany.
• ⁹ KTB Klinik für Tumorbiologie, Breisacher Str. 117, 79106, Freiburg Im Breisgau, Baden-Württemberg, Germany.